Lexeo Therapeutics(LXEO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXEO Lexeo Therapeutics

Market Closed 12-12 16:00:00 EST

9.77

-0.03

-0.31%

盘后9.79

+0.02+0.20%

17:28 EST

High10.02	Low9.48	Vol681.50K
Open9.78	D1 Closing9.80	Amplitude5.51%
Mkt Cap713.09M	Tradable Cap439.70M	Total Shares72.99M
T/O6.65M	T/O Rate1.51%	Tradable Shares45.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LXEO","market":"US","secType":"STK","nameCN":"Lexeo Therapeutics","latestPrice":9.77,"timestamp":1765573200000,"preClose":9.8,"halted":0,"volume":681497,"hourTrading":{"tag":"盘后","latestPrice":9.79,"preClose":9.77,"latestTime":"17:28 EST","volume":29409,"amount":287348.48,"timestamp":1765578504672},"delay":0,"floatShares":45005000,"shares":72987327,"eps":-2.45448,"marketStatus":"Market Closed","change":-0.03,"latestTime":"12-12 16:00:00 EST","open":9.78,"high":10.015,"low":9.475,"amount":6647149.319259,"amplitude":0.055102,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.45448,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1698984000000,"exchange":"NASDAQ","adjPreClose":9.8,"preHourTrading":{"tag":"盘前","latestPrice":9.8,"preClose":9.8,"latestTime":"09:28 EST","volume":13348,"amount":130572.485248,"timestamp":1765549680067},"postHourTrading":{"tag":"盘后","latestPrice":9.79,"preClose":9.77,"latestTime":"17:28 EST","volume":29409,"amount":287348.48,"timestamp":1765578504672},"volumeRatio":0.8261088785672724,"impliedVol":0.6924,"impliedVolPercentile":0.184},"requestUrl":"/m/hq/s/LXEO/wiki","defaultTab":"wiki","newsList":[{"id":"2590513785","title":"Lexeo Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590513785?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:27","pubTimestamp":1765456020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 07:27 ET (12:27 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2588145884","title":"Lexeo Therapeutics Hosts Virtual Clinician Event on PKP2-Associated Arrhythmogenic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588145884","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588145884?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853207,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. will host a virtual event titled \"A Clinician's Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy\" during the 22nd Global Cardiovascular Clinical Trialists  Forum on Tuesday, December 9th at 3 PM ET. The session will feature Dr. Victoria Parikh of Stanford University, who will discuss clinical management for patients with PKP2-associated arrhythmogenic cardiomyopathy. The event will be accessible to analysts and investors, and a replay will be available on Lexeo's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 04, 2025, and is solely responsible fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9v0MCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4139","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4588","LU2210150020.SGD","LXEO","LU2095319765.USD","LU0314104364.USD","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588731287","title":"Lexeo Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2588731287","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588731287?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:08","pubTimestamp":1764598080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 09:08 ET (14:08 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2584136718","title":"Lexeo Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2584136718","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584136718?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:07","pubTimestamp":1763640420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 07:07 ET (12:07 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2584334631","title":"Lexeo Therapeutics initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2584334631","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584334631?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:10","pubTimestamp":1763637038,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald initiated coverage of Lexeo Therapeutics (LXEO) with an Overweight rating and $19 price target Published first on TheFly – the ul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2584647279","title":"Optimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2584647279","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584647279?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:35","pubTimestamp":1763379343,"startTime":"0","endTime":"0","summary":"In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lexeo Therapeutics, Inc., with a price target of $13.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-lexeo-therapeutics-driven-by-high-dose-potential-and-superior-safety-profile-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-lexeo-therapeutics-driven-by-high-dose-potential-and-superior-safety-profile-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPN","LXEO"],"gpt_icon":0},{"id":"2581761980","title":"Lexeo Therapeutics Reports Decreased Losses and Strong Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2581761980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581761980?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:54","pubTimestamp":1762498462,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics, Inc. ( ($LXEO) ) has released its Q3 earnings. Here is a breakdown of the information Lexeo Therapeutics, Inc. presented to its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-reports-decreased-losses-and-strong-cash-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-reports-decreased-losses-and-strong-cash-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2581090850","title":"Lexeo Therapeutics unveils gene therapy advances targeting cardiac diseases with no existing treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2581090850","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581090850?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:49","pubTimestamp":1762444140,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. has provided an update on its gene therapy programs targeting cardiac diseases with significant unmet medical needs. The company highlighted LX2006, its clinical-stage program for Friedreich Ataxia  cardiomyopathy, the leading cause of death in individuals with FA. Interim clinical data indicate sustained or deepening improvements in both cardiac and neurological measures among most participants. The FDA has expressed openness to a Biologics License Application  submission for accelerated approval, incorporating data from ongoing and planned studies. Lexeo also reported progress on LX2020 for PKP2 arrhythmogenic cardiomyopathy, with safety and efficacy data expected in early January. The company emphasized the use of AAVrh10 vector technology, which has demonstrated increased cardiac targeting and favorable safety profiles in preclinical and clinical programs. You can access the full presentation through the link below.Disclaimer: This news brief was created by ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9WJjdQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2581084860","title":"Lexeo Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581084860","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581084860?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:27","pubTimestamp":1762388820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 19:27 ET (00:27 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2581722573","title":"Lexeo Therapeutics Q3 EPS $(0.33) Beats $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722573","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722573?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:37","pubTimestamp":1762346275,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.78 percent. This is a 62.92 percent increase over losses of $(0.89) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48649935/lexeo-therapeutics-q3-eps-0-33-beats-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2581722652","title":"Lexeo Therapeutics reports interim LX2006 trial data showing improvements in cardiac and neurologic measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722652","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722652?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:37","pubTimestamp":1762346232,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. reported a cash position of $122.8 million as of September 30, 2025, excluding $153.8 million in proceeds from an October 2025 public offering and concurrent PIPE. The company closed an oversubscribed $154 million equity financing in October 2025, which, combined with existing cash and investments, is expected to fund operations into 2028. Lexeo also announced business developments, including the completion of enrollment in the LX2020 HEROIC-PKP2 Phase I/II trial and FDA approval of a comparability report for LX2006 manufacturing processes. Interim clinical data for LX2006 showed a mean improvement in left ventricular mass index and stabilization or improvement in secondary cardiac biomarkers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL5tsSNr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","BK4139","IE00BKPKM429.USD","LU0314104364.USD","BK4112","LU2210149790.SGD","BK4588","LXEO","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581722920","title":"Lexeo Therapeutics Inc - EPS $-0.33 for Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722920?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:36","pubTimestamp":1762346215,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA6DVFRZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2581722614","title":"Press Release: Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722614?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:36","pubTimestamp":1762346160,"startTime":"0","endTime":"0","summary":"FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application. FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal study. LX2006 interim clinical data show clinically meaningful improvements across cardiac and neurologic measures of Friedreich ataxia, including left ventricular mass index and the modified Friedreich Ataxia Rating Scale. Completed enrollment of LX2020 HEROIC-PKP2 Phase I/II trial with ten participants dosed; interim data from low-dose cohort reported and additional clinical data from high-dose cohorts on track for January 2026. $154 million equity financing to support LX2006 registrational activities and further development of cardiac pipeline; in addition to Q3-25 end cash, cash equivalents an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","BK4139","LXEO","BK4535","BK4588","VT","BK4585","FA","BK4130","BK4539","LFT"],"gpt_icon":0},{"id":"2580624599","title":"Lexeo Therapeutics selloff looks ‘highly unwarranted,’ says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2580624599","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580624599?lang=en_us&edition=fundamental","pubTime":"2025-11-04 01:05","pubTimestamp":1762189513,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterated a Buy rating and $13 price target on Lexeo Therapeutics (LXEO), saying Monday’s selloff looks “highly unwarranted” given...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-selloff-looks-highly-unwarranted-says-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-selloff-looks-highly-unwarranted-says-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2577824472","title":"Lexeo Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2577824472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577824472?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:21","pubTimestamp":1761045660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 21, 2025 07:21 ET (11:21 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2577898016","title":"Press Release: Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2577898016","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577898016?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:05","pubTimestamp":1760990700,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct. 20, 2025  -- Lexeo Therapeutics, Inc.  , a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, before deducting underwriting discounts and commission and other expenses payable by Lexeo in connection with the transaction and including the full exercise of the underwriters' option to purchase additional shares.Leerink Partners, Cantor, Stifel and Oppenheimer & Co. acted as joint book-running managers for the public offering. Baird acted as lead manager for the public offering. Leerink Partners served as sole Placement Agent in connection with the concurrent private placement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","FA","BK4539","LXEO","BK4130"],"gpt_icon":0},{"id":"2576993650","title":"Lexeo Therapeutics Executives Make Major Stock Moves!","url":"https://stock-news.laohu8.com/highlight/detail?id=2576993650","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576993650?lang=en_us&edition=fundamental","pubTime":"2025-10-18 10:02","pubTimestamp":1760752926,"startTime":"0","endTime":"0","summary":"New insider activity at Lexeo Therapeutics, Inc. ( ($LXEO) ) has taken place on October 17, 2025. In a series of significant stock transactions at ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/lexeo-therapeutics-executives-make-major-stock-moves-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/lexeo-therapeutics-executives-make-major-stock-moves-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2576038060","title":"Lexeo Therapeutics Chief Development Officer Sandi See Tai Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2576038060","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576038060?lang=en_us&edition=fundamental","pubTime":"2025-10-18 07:30","pubTimestamp":1760743812,"startTime":"0","endTime":"0","summary":"Sandi See Tai, Chief Development Officer of Lexeo Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL9YFwsP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2576060755","title":"Lexeo Therapeutics CEO Richard Nolan Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2576060755","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576060755?lang=en_us&edition=fundamental","pubTime":"2025-10-18 07:26","pubTimestamp":1760743604,"startTime":"0","endTime":"0","summary":"Richard Nolan Townsend, Chief Executive Officer and Director of Lexeo Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL7ZTS8r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2576688560","title":"Lexeo Therapeutics price target lowered to $18 from $20 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2576688560","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576688560?lang=en_us&edition=fundamental","pubTime":"2025-10-18 01:15","pubTimestamp":1760721312,"startTime":"0","endTime":"0","summary":"Leerink analyst Mani Foroohar lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $18 from $20 and keeps an Outperform rating on the sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-18-from-20-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-18-from-20-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexeotx.com","stockEarnings":[{"period":"1week","weight":0.0449},{"period":"1month","weight":0.0608},{"period":"3month","weight":0.8861},{"period":"6month","weight":1.4797},{"period":"1year","weight":0.3703},{"period":"ytd","weight":0.4848}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.","exchange":"NASDAQ","name":"Lexeo Therapeutics","nameEN":"Lexeo Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexeo Therapeutics(LXEO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexeo Therapeutics(LXEO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexeo Therapeutics,LXEO,Lexeo Therapeutics股票,Lexeo Therapeutics股票老虎,Lexeo Therapeutics股票老虎国际,Lexeo Therapeutics行情,Lexeo Therapeutics股票行情,Lexeo Therapeutics股价,Lexeo Therapeutics股市,Lexeo Therapeutics股票价格,Lexeo Therapeutics股票交易,Lexeo Therapeutics股票购买,Lexeo Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexeo Therapeutics(LXEO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexeo Therapeutics(LXEO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}